Ariosa Diagnostics, Inc. v. Sequenom, Inc.

Ariosa Diagnostics, Inc. v. Sequenom, Inc. was a pivotal United States patent case addressing the patent eligibility of diagnostic methods that apply naturally occurring biomarker information. The litigation arose from a dispute between Ariosa Diagnostics, Inc. and Sequenom, Inc. over patents claiming a method for detecting fetal cell-free fetal DNA in maternal blood, implicating issues of Federal Circuit jurisprudence, Supreme Court precedent, and patent practice across biotechnology and pharmaceutical industries.

Background

Sequenom, a molecular diagnostics company spun out from VeraMed Laboratories and connected to inventors at Stanford University and UCSF, obtained patents directed to a method of detecting fetal DNA fragments in maternal plasma after studies involving researchers associated with Stephen Quake and Dennis Lo. The claimed invention capitalized on prior discoveries reported in journals associated with Nature and The Lancet about circulating cell-free DNA and the medical practice of prenatal screening, with commercial relevance to companies such as Roche, Abbott Laboratories, and Illumina. Sequenom asserted patent rights against Ariosa, a competitor developing noninvasive prenatal testing technology in a market influenced by regulatory frameworks of the Food and Drug Administration and reimbursement by CMS policies.

District Court Proceedings

The dispute was litigated in the Northern District of California, where Sequenom sued Ariosa for patent infringement and Ariosa counterclaimed challenging validity under 35 U.S.C. § 101 and other statutory grounds. The district court considered precedent from the Supreme Court including decisions such as Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Association for Molecular Pathology v. Myriad Genetics, Inc. in evaluating whether the claims merely recited a natural phenomenon—namely fetal DNA in maternal plasma—or implemented an inventive application. Counsel for Sequenom included attorneys experienced before the Federal Circuit and advocates who had briefed matters in the Supreme Court, while Ariosa relied on amici briefs from organizations like the ACLU and industry trade groups including the BIO.

Federal Circuit Decision

On appeal, a three-judge panel of the Federal Circuit (Judges Linn, Reyna, and Hughes) affirmed the district court's judgment that the asserted claims were invalid under § 101. The court applied the two-step framework from Mayo and Alice Corp. v. CLS Bank International, determining that the claims were directed to a natural phenomenon and that the additional claimed steps were routine, conventional laboratory techniques performed in the field of molecular diagnostics. The Federal Circuit's opinion engaged with prior Federal Circuit precedents on biotechnology patents and touched on patent doctrines developed in cases like In re Bilski and decisions involving genomics and diagnostic method claims, provoking commentary from academics at institutions such as Harvard University and Stanford Law School.

Supreme Court Consideration and Aftermath

Sequenom sought certiorari to the Supreme Court, and the petition attracted attention from major stakeholders including PhRMA, AMA, and university technology transfer offices at institutions like MIT and Johns Hopkins University. The Supreme Court denied certiorari, leaving the Federal Circuit ruling intact and prompting debate among jurists, commentators at outlets such as The New York Times and The Wall Street Journal, and testimony before committees of the United States Senate and United States House of Representatives concerning patent reform proposals. The denial influenced subsequent Federal Circuit panels and district courts considering § 101 challenges in diagnostics and personalized medicine litigation involving firms like Guardant Health and Foundation Medicine.

Legal Analysis and Implications

Legal scholars analyzed the decision in light of the Supreme Court's § 101 jurisprudence, contrasting the Federal Circuit's application of the Mayo/Alice framework with earlier decisions permitting claims to applied biological processes. Law reviews at Columbia Law School and Yale Law School critiqued the court's treatment of inventive concept and conventionality, while policy organizations such as the Electronic Frontier Foundation weighed in on innovation incentives. The case highlighted tension between patent eligibility under § 101 and patentability conditions under 35 U.S.C. § 102 and 35 U.S.C. § 103, affecting doctrines including enablement and written description as articulated in cases like KSR International Co. v. Teleflex Inc. and Alice.

Impact on Biotechnology and Patent Practice

The decision had immediate effects on patent drafting, prosecution, and litigation strategy within the biotechnology industry, prompting patent practitioners at firms like Fenwick & West and WilmerHale to emphasize claims to novel, concrete technical applications and instrument limitations. Companies in molecular diagnostics, genomics startups, and university technology transfer offices revisited claim scope, focusing on apparatus claims and specific assay improvements to withstand § 101 scrutiny. Investors in life sciences, including venture capital firms such as Third Rock Ventures and Atlas Venture, adjusted valuation assumptions for diagnostics ventures, and trade associations such as BIO lobbied for legislative clarification of patent-eligibility standards to support translational research and commercialization. Category:United States patent case law